Zoetis Inc. Overview and Stock Performance
Zoetis Inc. (ZTS), valued at $65.3 billion, is a prominent name in the animal health sector. The company, which has its headquarters in Parsippany, New Jersey, specializes in a range of products including medicines, vaccines, diagnostics, and health solutions tailored for both livestock and pets. Their clientele includes veterinarians, livestock farmers, and pet owners, and they’ve developed a broad selection of offerings that cover areas like vaccines, parasite control, dermatology, and advanced diagnostic tools.
In the last year, Zoetis’s stock performance has not mirrored the broader market. Over the past 52 weeks, ZTS shares dropped by 19.6%, while the S&P 500 saw a 19.6% gain. Year-to-date, the decline stands at 8.6%, in contrast to an 8.7% rise in the S&P index. Additionally, the share price has underperformed against the Healthcare Select Sector SPDR Fund (XLV), which saw a 12.8% decrease in the same period.
Despite a stronger-than-anticipated second-quarter adjusted EPS of $1.76 and a revenue of $2.5 billion, there was a 3.8% drop in share price on August 5. This decline was attributed to a downturn in specific product lines. Notably, U.S. sales from monoclonal antibody treatments for OA pain experienced a decline, which impacted the overall growth of 9% in companion animal sales. Additionally, the sales of livestock products in the U.S. have sharply decreased by 21%, now standing at $180 million.
Looking ahead, analysts expect Zoetis’s adjusted EPS to rise by 7.4% in the fiscal year ending December 2025, reaching $6.36. Historically, the company has exceeded revenue expectations consistently over the past four quarters, which is a positive sign.
A survey of 15 analysts covering the stock currently gives it a consensus rating of “strong buy,” which is based on 11 “strong buy” ratings, 1 “medium buy,” and 3 “holds.” Interestingly, there has been a slight decrease in bullish sentiment compared to three months ago when there were 13 “strong buy” ratings.
On August 7, UBS analyst Andrea Alfonso reaffirmed a “hold” rating for Zoetis, with a price target set at $165. As it stands, the stock is trading below the average price target of $193.71. A high target of $230 suggests a potential upside of about 55.9% from current price levels.
